Clinical trials: Mammary Cancer
Breast Cancer
A Study of Pemetrexed and Cyclophosphamide Given Every 21 Days in Advanced Breast Cancer Patients
This is the phase 2 portion of a phase 1/2 trial, testing the use of pemetrexed and cyclophosphamide in combination for the treatment of advanced breast cancer.
- Trial name
- NCT00190671
- Testing
- pemetrexed, cyclophosphamide
- Where
- 13 sites in Austria, Czechia and 4 more
- Volunteers
- 103 people
- Sponsor
- Eli Lilly and Company
Metastatic Breast Cancer
Phase II PEMBROLIZUMAB + PALLIATIVE RADIOTHERAPY IN BC
This research study is studying radiation therapy in combination with an immunotherapy as a possible treatment for metastatic hormone receptor (HR) positive, HER2-negative breast cancer.
- Trial name
- NCT03051672
- Testing
- Pembrolizumab, Palliative radiotherapy
- Where
- United States
- Volunteers
- 8 people
- Sponsor
- Dana-Farber Cancer Institute
Metastatic Breast Cancer
A Study Evaluating the Efficacy and Safety of Bevacizumab in Combination With Chemotherapy in Untreated Metastatic Breast Cancer (RIBBON 1)
This is a Phase III, multicenter, randomized, placebo-controlled trial designed to evaluate the efficacy and safety of bevacizumab in combination with chemotherapy compared with chemotherapy alone in subjects with previously…
- Trial name
- NCT00262067
- Testing
- Bevacizumab, Chemotherapy
- Where
- 92 sites in United States, Australia and 20 more
- Volunteers
- 1,237 people
- Sponsor
- Genentech, Inc.
Breast Cancer, Precancerous Condition
Broccoli Sprout Extract in Treating Women Who Have Had a Mammogram and Breast Biopsy
RATIONALE: Broccoli sprout extract supplements may slow the growth of tumor cells or abnormal cells and may be an effective treatment for ductal carcinoma in situ and/or atypical ductal hyperplasia.
- Trial name
- NCT00843167
- Testing
- broccoli sprout extract
- Where
- United States
- Volunteers
- 54 people
- Sponsor
- OHSU Knight Cancer Institute
Neoplasms, Breast
A Study to Compare the Safety and Efficacy of an Aromatase Inhibitor in Combination With Lapatinib, Trastuzumab or Both for the Treatment of Hormone Receptor Positive, HER2+ Metastatic Breast Cancer
A study to compare the safety and efficacy of an aromatase inhibitor in combination with lapatinib, trastuzumab or both for the treatment of hormone receptor positive, HER2+ metastatic breast cancer (MBC).
- Trial name
- NCT01160211
- Testing
- Lapatinib, Trastuzumab, Aromatase Inhibitor
- Where
- 110 sites in United States, Argentina and 27 more
- Volunteers
- 369 people
- Sponsor
- Novartis Pharmaceuticals
Melanoma, Meningioma
T Cell Receptor Immunotherapy Targeting NY-ESO-1 for Patients With NY-ESO-1 Expressing Cancer
Background: The National Cancer Institute (NCI) Surgery Branch has developed an experimental therapy for treating patients with cancer that involves taking white blood cells from the patient, growing them in the laboratory in…
- Conditions
- Melanoma, Meningioma, Breast Cancer, Non-Small Cell Lung Cancer
- Trial name
- NCT01967823
- Testing
- Anti-NY ESO-1 mTCR PBL, Cyclophosphamide, Fludarabine
- Where
- United States
- Volunteers
- 11 people
- Sponsor
- National Cancer Institute (NCI)
Breast Cancer, Breast Neoplasm
Primary Chemotherapy With Docetaxel-Capecitabine and Doxorubicin-Cyclophosphamide in Breast Cancer
This study will assess the usefulness of a technique called complementary deoxyribonucleic acid (cDNA) microarray-an examination of a wide array of genes to identify disease-associated patterns-for measuring tumor response to…
- Trial name
- NCT00005908
- Testing
- Docetaxel - Dose A, Anastrozole, cyclophosphamide
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- National Cancer Institute (NCI)
Cancer Related Fatigue
Trial of Exercise to Reduce Cancer Related Fatigue in Breast Cancer
Like other cancer treatments, radiation therapy can make people feel fatigued, or tired. The investigators think that moderate exercise, done 15 minutes at a time, can reduce the fatigue.
- Trial name
- NCT02846389
- Testing
- Moderate Exercise
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- Hackensack Meridian Health
Her2-Positive Breast Cancer
Phase 2 Trial of Pertuzumab and Trastuzumab With Weekly Paclitaxel and Chemotherapy for HER2 Positive Breast Cancer
The main goal of this clinical trial is to test if adding pertuzumab (Perjeta), improves the anticancer activity of the combination chemotherapy regimen of trastuzumab (Herceptin) concomitant with paclitaxel, 5-fluorouracil…
- Trial name
- NCT01855828
- Testing
- Pertuzumab, Trastuzumab, Paclitaxel
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- Yale University
Breast Cancer, Breast Tumors
Re-expression of ER in Triple Negative Breast Cancers
Patients are being asked to take part in this study because they have metastatic breast cancer that is triple negative (does not express estrogen receptor (ER), progesterone receptor (PR) or HER2).
- Conditions
- Breast Cancer, Breast Tumors, Breast Neoplasms
- Trial name
- NCT01194908
- Testing
- Decitabine, LBH589, Tamoxifen
- Where
- United States
- Volunteers
- 5 people
- Sponsor
- Emory University
Breast Cancer
Fulvestrant Plus Enzalutamide in ER+/Her2- Advanced Breast Cancer
A phase 2 study to evaluate the tolerability and clinical activity of adding enzalutamide to fulvestrant treatment in women with advanced breast cancer that are ER and/or PR positive and Her2 normal.
- Trial name
- NCT02953860
- Testing
- Fulvestrant with Enzalutamide
- Where
- 3 sites in United States
- Volunteers
- 32 people
- Sponsor
- University of Colorado, Denver
Cognitive Impairment
Gene Expression, Meditative Movement, and Emotional Distress (GME)
Study Title: Gene Expression, Meditative Movement and Emotional Distress (GME) Background and Objectives: Breast cancer survivors (BCS) often report decrements in cognitive functioning.
- Trial name
- GME (NCT04213872)
- Testing
- Meditative Movement
- Where
- United States
- Volunteers
- 27 people
- Sponsor
- Arizona State University
Breast Cancer Screening, Colon Cancer Screening
Evaluating the Shared Decision Making Process Scale in Cancer Screening Decisions
The purpose of this retrospective observational study is to evaluate the performance of the Shared Decision Making Process scale in a sample of patients who have received a decision aid about the decision to screen or not screen…
- Conditions
- Breast Cancer Screening, Colon Cancer Screening, Prostate Cancer Screening
- Trial name
- NCT04601272
- Testing
- Decision aid
- Where
- United States
- Volunteers
- 240 people, healthy volunteers welcome
- Sponsor
- Massachusetts General Hospital
Breast Cancer
PEAK PlasmaBlade™ 4.0 Versus Traditional Electrosurgery in Lumpectomy
The purpose of this clinical study is to quantify the difference in thermal injury depth at the surgical margin in breast lumpectomy specimens excised with the PlasmaBlade; to subjectively assess histopathologic sample quality…
- Trial name
- PRECISE (NCT00960154)
- Testing
- PEAK PlasmaBlade, Traditional Electrosurgery with scalpel
- Where
- 2 sites in United States
- Volunteers
- 50 people
- Sponsor
- Medtronic Surgical Technologies
Male Breast Cancer, Recurrent Breast Cancer
Vorinostat in Treating Patients With Stage IV Breast Cancer Receiving Hormone Therapy
This pilot clinical trial studies vorinostat in treating patients with stage IV breast cancer receiving hormone therapy. Vorinostat may help hormone therapy work better by making tumor cells more sensitive to the drug.
- Conditions
- Male Breast Cancer, Recurrent Breast Cancer, Stage IV Breast Cancer
- Trial name
- NCT01720602
- Testing
- vorinostat, anastrozole, letrozole
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- University of Washington
BRCA1 Gene Mutation, BRCA2 Gene Mutation
Pembrolizumab in Treating Participants With Metastatic, Recurrent or Locally Advanced Cancer and Genomic Instability
This phase II trial studies how well pembrolizumab works in treating participants with cancer that has spread to other places in the body, has come back or has spread to nearby tissues or lymph nodes.
- Conditions
- BRCA1 Gene Mutation, BRCA2 Gene Mutation, Locally Advanced Solid Neoplasm, Metastatic Malignant Solid Neoplasm
- Trial name
- NCT03428802
- Testing
- Laboratory Biomarker Analysis, Pembrolizumab
- Where
- 2 sites in United States
- Volunteers
- 21 people
- Sponsor
- Rutgers, The State University of New Jersey
Breast Cancer
Trastuzumab Deruxtecan (DS-8201a) Versus Investigator's Choice for HER2-low Breast Cancer That Has Spread or Cannot be Surgically Removed [DESTINY-Breast04]
This study will compare DS-8201a to physician choice standard treatment. Participants must have HER2-low breast cancer that has been treated before.
- Trial name
- NCT03734029
- Testing
- Trastuzumab deruxtecan (DS-8201a), Capecitabine, Eribulin
- Where
- 208 sites in United States, Austria and 18 more
- Volunteers
- 557 people
- Sponsor
- Daiichi Sankyo
Breast Cancer
A Study of Avastin (Bevacizumab) and Sequential Chemotherapy in Patients With Primary HER2 Negative Operable Breast Cancer.
This single arm study will assess the efficacy and safety of a combination of Avastin and docetaxel following cyclophosphamide and doxorubicin, in patients with HER2 negative operable breast cancer.
- Trial name
- NCT00559754
- Testing
- bevacizumab [Avastin], Docetaxel, Standard chemotherapy
- Where
- 6 sites in Spain
- Volunteers
- 72 people
- Sponsor
- Hoffmann-La Roche
Breast Neoplasms
Evaluation of Cryoprotection Induced Nail Toxicity Docetaxel Low Cumulative Dose
For the specific patient population studied receiving 5-Fluorouracil, epirubicin and cyclophosphamide - Docetaxel sequence (cumulative dose <300 mg / m2), using a cryoprotection has never been assessed.
- Trial name
- BANQUISE (NCT02283983)
- Testing
- mittens and booties, cooling helmet
- Where
- 10 sites in France
- Volunteers
- 319 people
- Sponsor
- Centre Hospitalier Departemental Vendee
Breast Cancer, Gynecologic Cancer
Mindful After Cancer: A Mindfulness-based Therapy Intervention for Sexual Health After Cancer
The objectives of this study are to: 1) adapt a mindfulness-based therapy program designed to help women manage their sexual and body image concerns after cancer (Mindful After Cancer, MAC) to a videoconference format and 2)…
- Trial name
- MAC (NCT04559854)
- Testing
- Mindful After Cancer
- Where
- United States
- Volunteers
- 22 people
- Sponsor
- Oregon State University
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.